What is HC Wainwright’s Estimate for PSTV FY2028 Earnings?

Plus Therapeutics, Inc. (NASDAQ:PSTV) – Research analysts at HC Wainwright issued their FY2028 EPS estimates for Plus Therapeutics in a research note issued to investors on Friday, November 15th. HC Wainwright analyst S. Lee forecasts that the company will earn $0.28 per share for the year. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Plus Therapeutics’ current full-year earnings is ($2.00) per share.

Separately, Ascendiant Capital Markets dropped their price target on shares of Plus Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd.

Plus Therapeutics Stock Up 1.7 %

PSTV stock opened at $1.19 on Monday. The company has a market capitalization of $7.02 million, a PE ratio of -0.47 and a beta of 0.69. The stock’s 50 day moving average is $1.40 and its two-hundred day moving average is $1.66. Plus Therapeutics has a 52-week low of $1.15 and a 52-week high of $2.67.

Institutional Trading of Plus Therapeutics

An institutional investor recently bought a new position in Plus Therapeutics stock. AIGH Capital Management LLC bought a new position in Plus Therapeutics, Inc. (NASDAQ:PSTV) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned approximately 9.98% of Plus Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 3.28% of the company’s stock.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.